01.23.24
Iconic skincare brand RoC is to be invested by Bridgepoint Europe VII (BE VII), a fund focused on investing in mid-market growth businesses. Gryphon Investors’ current majority shareholdings in RoC will go to Bridgepoint as part of the transaction. The transaction is expected to close in February 2024. Financial terms were not disclosed.
Gryphon Investors acquired RoC from Johnson & Johnson in 2020 and established the brand as an independent business and supporting RoC in a revival of the brand’s positioning in organic growth. Since 2020, RoC’s revenue has grown by 70%, and the dermo-cosmetic facial skincare market in the US and Europe is expected to grow.
Bridgepoint hopes to support RoC’s growth in European markets. Currently, RoC is sold globally, including the US, Canada, UK and Europe, China, and Australia.
“With Bridgepoint’s deep expertise in the dermatology sector and its strong European presence, RoC is poised to capitalize on the promising growth opportunities that lie ahead,” commented RoC Skincare CEO Fernando Acosta.
Bridgepoint partner Fabrice Turcq said, “Under Fernando’s leadership, RoC has become an impressive standalone business with a rich European heritage and dermatology expertise... With Bridgepoint’s support, RoC is poised to accelerate growth in Europe and beyond, strengthen its online presence and expand its product offering.”
About the Company:
RoC offers dermatologist-backed, clinically proven skin health solutions that focus on aging skin. RoC is a pioneer of the dermo-cosmetic world, creating the first hypoallergenic skincare products, stabilized Retinol products and broad-spectrum UV protection.Gryphon Investors acquired RoC from Johnson & Johnson in 2020 and established the brand as an independent business and supporting RoC in a revival of the brand’s positioning in organic growth. Since 2020, RoC’s revenue has grown by 70%, and the dermo-cosmetic facial skincare market in the US and Europe is expected to grow.
Bridgepoint hopes to support RoC’s growth in European markets. Currently, RoC is sold globally, including the US, Canada, UK and Europe, China, and Australia.
A Strategic Investment:
RoC will benefit from Bridgepoint’s strong presence in Europe and its expertise in the dermatology sectors. Bridgepoint plans to build in RoC’s growing track record and support of businesses in the dermatology markets, including HTL, a leading producer of high-quality hyaluronic acid; and Vivacy global personal healthcare company.“With Bridgepoint’s deep expertise in the dermatology sector and its strong European presence, RoC is poised to capitalize on the promising growth opportunities that lie ahead,” commented RoC Skincare CEO Fernando Acosta.
Bridgepoint partner Fabrice Turcq said, “Under Fernando’s leadership, RoC has become an impressive standalone business with a rich European heritage and dermatology expertise... With Bridgepoint’s support, RoC is poised to accelerate growth in Europe and beyond, strengthen its online presence and expand its product offering.”